• +1-646-491-9876
    • +91-20-67278686

    Search

    Constipation - Pipeline Review, H1 2017

    Constipation - Pipeline Review, H1 2017

    • Report Code ID: RW0001689410
    • Category Healthcare
    • No. of Pages 108
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H1 2017, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

    Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 7, 8, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

    Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
    - The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Constipation - Overview
    Constipation - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Constipation - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Constipation - Companies Involved in Therapeutics Development
    Albireo Pharma Inc
    Ardelyx Inc
    Assembly Biosciences Inc
    Astellas Pharma Inc
    Braintree Laboratories Inc
    CJ HealthCare Corp
    Dong-A Socio Holdings Co Ltd
    EA Pharma Co Ltd
    Ironwood Pharmaceuticals Inc
    Lipid Pharmaceuticals ehf
    Motus Therapeutics Inc
    NGM Biopharmaceuticals Inc
    RaQualia Pharma Inc
    Sanwa Kagaku Kenkyusho Co Ltd
    Shire Plc
    SK Biopharmaceuticals Co Ltd
    Sucampo Pharmaceuticals Inc
    Sumitomo Dainippon Pharma Co Ltd
    Synthetic Biologics Inc
    Torrent Pharmaceuticals Ltd
    Yuhan Corp
    Constipation - Drug Profiles
    5-BIOP - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AJG-555 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-7663 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLI-400 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLI-801 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CJ-14199 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DA-6886 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DSP-6952 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elobixibat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ENT-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    J-027 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    linaclotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lovastatin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LP-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lubiprostone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naronapride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NGM-282 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    prucalopride succinate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    prucalopride succinate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    relamorelin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    relenopride hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RQ-00000010 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SK-1202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tenapanor hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YH-12852 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Constipation - Dormant Projects
    Constipation - Product Development Milestones
    Featured News & Press Releases
    Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan
    Jan 30, 2017: Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
    Jan 26, 2017: U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS (linaclotide) for Adults with Chronic Idiopathic Constipation
    Dec 22, 2016: Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
    Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
    Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting
    Oct 03, 2016: Albireo Announces Positive Top-Line Phase 3 Results for Elobixibat in Japan
    Sep 30, 2016: EA Pharma and Mochida Pharmaceutical Announce the Results of Phase 3 Study of AJG533 for Chronic Constipation Conducted in Japan
    Aug 19, 2016: The First Dosing of RQ-00000010 at Virginia Commonwealth University Initiated
    Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation
    Jun 09, 2016: Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
    May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
    May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016
    May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
    May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Constipation, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Constipation - Pipeline by Albireo Pharma Inc, H1 2017
    Constipation - Pipeline by Ardelyx Inc, H1 2017
    Constipation - Pipeline by Assembly Biosciences Inc, H1 2017
    Constipation - Pipeline by Astellas Pharma Inc, H1 2017
    Constipation - Pipeline by Braintree Laboratories Inc, H1 2017
    Constipation - Pipeline by CJ HealthCare Corp, H1 2017
    Constipation - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
    Constipation - Pipeline by EA Pharma Co Ltd, H1 2017
    Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
    Constipation - Pipeline by Lipid Pharmaceuticals ehf, H1 2017
    Constipation - Pipeline by Motus Therapeutics Inc, H1 2017
    Constipation - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
    Constipation - Pipeline by RaQualia Pharma Inc, H1 2017
    Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2017
    Constipation - Pipeline by Shire Plc, H1 2017
    Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
    Constipation - Pipeline by Sucampo Pharmaceuticals Inc, H1 2017
    Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Constipation - Pipeline by Synthetic Biologics Inc, H1 2017
    Constipation - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
    Constipation - Pipeline by Yuhan Corp, H1 2017
    Constipation - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Constipation, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Albireo Pharma Inc
    Ardelyx Inc
    Assembly Biosciences Inc
    Astellas Pharma Inc
    Braintree Laboratories Inc
    CJ HealthCare Corp
    Dong-A Socio Holdings Co Ltd
    EA Pharma Co Ltd
    Ironwood Pharmaceuticals Inc
    Lipid Pharmaceuticals ehf
    Motus Therapeutics Inc
    NGM Biopharmaceuticals Inc
    RaQualia Pharma Inc
    Sanwa Kagaku Kenkyusho Co Ltd
    Shire Plc
    SK Biopharmaceuticals Co Ltd
    Sucampo Pharmaceuticals Inc
    Sumitomo Dainippon Pharma Co Ltd
    Synthetic Biologics Inc
    Torrent Pharmaceuticals Ltd
    Yuhan Corp

    Request for Sample

    Report Url http://www.reportsweb.com//constipation-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//constipation-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//constipation-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments